ICON Data Sample Clauses

ICON Data. Subject to applicable laws governing patient confidentiality and to the extent necessary for ARIAD to comply with applicable statutes, laws, regulations, ordinances and guidelines governing Regulatory Approval of AP23573, ICON shall provide to ARIAD: (a) in readable electronic database format, all clinical safety data (including Adverse Events) from its Clinical Trials relating to ICON Licensed Products, (b) copies of all investigator safety letters provided by ICON to its clinical investigators in connection with Clinical Trials of ICON Licensed Products, and (c) only to the extent reasonably necessary for ARIAD to obtain Regulatory Approval of AP23573, summaries of data generated by ICON in connection with its preclinical studies of any product containing AP23573 (collectively, “ICON Data”). ICON Data shall be treated as Confidential Information of ICON, and ARIAD shall maintain such ICON Data disclosed to it pursuant to this Section 3.3.5 in confidence and shall not use or disclose it to any Third Party other than to disclose, itself or through its agent, such ICON Data, after obtaining assurances that such ICON Data will be afforded confidential treatment by the recipient at least as restrictive as the treatment afforded Confidential Information hereunder, to its Exclusive Licensees, Pharmaceutical Partners, other licensees outside the Licensed Field or any Regulatory Authority solely as required in order for such recipient to obtain or grant, as the case may be, Regulatory Approval of a product containing AP23573; provided, that ARIAD shall not be required to obtain assurances of confidentiality from any Regulatory Authority. For clarity, nothing contained in this Agreement shall prohibit ARIAD from filing with any Regulatory Authority, any information that ARIAD reasonably believes it is required to file under applicable laws, rules or regulations. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Exchange Act.
Sample 1
AutoNDA by SimpleDocs

Related to ICON Data

  • Client Data 8.1. Fund (i) will provide or ensure that other Persons provide all Client Data to SS&C ALPS in an electronic format that is acceptable to SS&C ALPS (or as otherwise agreed in writing) and (ii) confirm that each has the right to share such Client Data. As between SS&C ALPS and Fund, all Client Data shall remain the property of the Fund to which such Client Data relate. Client Data shall not be used or disclosed by SS&C ALPS other than in connection with providing the Services and as permitted under Section 11.2. SS&C ALPS shall be permitted to act upon instructions from Management with respect to the disclosure or disposition of Client Data related to Fund, but may refuse to act upon such instructions where it doubts, in good faith, the authenticity or authority of such instructions.

  • Technical Data For the purpose of this Agreement, "TECHNICAL DATA" shall mean all information of the Company in written, graphic or tangible form relating to any and all products which are developed, formulated and/or manufactured by the Company, as such information exists as of the Effective Date or is developed by the Company during the term hereof.

  • Customer Data Customer shall remain the sole and exclusive owner of all Customer Data and other Confidential Information (as hereinafter defined), regardless of whether such data is maintained on magnetic tape, magnetic disk, or any other storage or processing device. All such Customer Data and other Confidential Information shall, however, be subject to regulation and examination by the appropriate auditors and regulatory agencies to the same extent as if such information were on Customer's premises. "Customer Data" means any and all data and information of any kind or nature submitted to M&I by Customer, or received by M&I on behalf of Customer, in connection with the Services.

  • User Data “User Data” shall mean any Personal Data or other data or information collected by or on behalf of any Acquired Corporation from users of any Acquired Corporation website.

  • Interactive Data The interactive data in eXtensible Business Reporting Language included as an exhibit to the Registration Statement or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

  • Data The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are derived. The Company has obtained the written consent to the use of such data from such sources to the extent necessary.

  • Contact Information Following are the Mxxxxx Sxxxxxx departments involved in servicing the Funds and the corresponding contact information. Abbreviation Department Primary Contact Telephone E-mail Futures Desk MSC Futures Trading Desk Bxxxx Xxxxxxx Dxxxxx Xxxxxxxxx 212.761.1782 212.761.2248 Bxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Dxxxxx.Xxxxxxxxx@xxxxxxxxxxxxx.xxx Futures Ops MSC Futures Operations Sxxxx Xxxxxxx Exxx Xxxxx 212.276.0477 212.276.0578 Sxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Exxx.Xxxxx@xxxxxxxxxxxxx.xxx FX Desk MSC Foreign Exchange Trading Desk Mxxxxxx Xxxxxxx 212.761.2700 Mxxxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx FX Ops MSC Foreign Exchange Operations Jxxx Xxxxx 718.754.4868 Jxxx.Xxxxx@xxxxxxxxxxxxx.xxx MF Accounting Mxxxxx Sxxxxxx Managed Futures Accounting Jxx Xxxxxxxx Kxxxx Xxxxxx 917.790.5702 917.790.5701 Jxx.Xxxxxxxx@xxxxxxxxxxxxx.xxx Kxxxx.Xxxxxx@xxxxxxxxxxxxx.xxx MF Ops Mxxxxx Sxxxxxx Managed Futures Operations Lxxxx Xxxxx 212.905.2720 Lxxxx.Xxxxxxxxx@xxxxxxxxxxxx.xxx MF Prod Org Mxxxxx Sxxxxxx Managed Futures Product Origination Pxxxxxx Xxxx 212.905.2736 Pxxxxxx.Xxxx@xxxxxxxxxxxxx.xxx MF Strat Plan Mxxxxx Sxxxxxx Managed Futures Strategic Planning Cxxxx Xxxxx 212.905.2731 Cxxxx.Xxxxx@xxxxxxxxxxxxx.xxx FUND ACCOUNTS: Account Configuration · Futures and Futures Options Trading - For each CTA trading program three Fund trading accounts will be assigned. A MS&Co segregated account, prefix 052. A MS&Co secured account, prefix 05A. A MSIL non-regulated (by the CFTC) account, prefix 045. · FX (Non-Options) Trading - One Fund account for each CTA trading program will be assigned at MS&Co, prefix 058. · FX Options Trading – One Fund account for each CTA trading program will be assigned at MSCG (if needed), prefix 057. · Excess and FX Custody Accounts – For each CTA trading program two Fund accounts will be set up at MS&Co. One account will be designated as a custody account for MS&Co FX. MF Ops will maintain equity in the custody account sufficient to cover margin requirements of the FX trading account. The second account will contain the balance of excess equity that is not required in the custody and futures trading accounts. Statements · Futures – The CTA should contact Futures Ops regarding access to Fund futures account statements. · FX – The CTA should contact FX Ops regarding access to Fund FX account statements. · Excess and Custody – The CTA should contact MF Ops regarding access to the Fund account statements at MS&Co.

  • Reference Data Each reference in this Lease to any of the terms and titles contained in this Article shall be deemed and construed to incorporate the data stated following that term or title in this Article.

  • Monthly Data Download Not later than fifteen (15) days after the end of each month, beginning with the month in which the Commencement Date occurs and ending with the Final Shared-Loss Month, Assuming Institution shall provide Receiver:

  • Product Information Galapagos recognizes that by reason of, inter alia, Xxxxxx’x status as an exclusive licensee pursuant to the grants under Section 5.2, Xxxxxx has an interest in Galapagos’ retention in confidence of certain information of Galapagos. Accordingly, during the Term, Galapagos shall, and shall cause its Affiliates and its and their respective officers, directors, employees, and agents to, keep completely confidential, and not publish or otherwise disclose, and not use directly or indirectly for any purpose other than to fulfill Galapagos’ obligations hereunder any Information owned or otherwise Controlled by Galapagos or any of its Affiliates specifically relating to any Licensed Compound or Licensed Product, or the Exploitation of any of the foregoing (the “Product Information”); except to the extent (x) the Product Information is in the public domain through no fault of Galapagos, its Affiliates or any of its or their respective officers, directors, employees, or agents; (y) such disclosure or use is expressly permitted under Section 9.3, or (z) such disclosure or use is otherwise expressly permitted by the terms of this Agreement. For purposes of Section 9.3, Xxxxxx shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Galapagos shall be deemed to be the receiving Party with respect thereto. For further clarification, (i) without limiting this Section 9.1, to the extent Product Information is disclosed by Galapagos to Xxxxxx pursuant to this Agreement, such information shall, subject to the other terms and conditions of this Article 9, also constitute Confidential Information of Galapagos with respect to the use and disclosure of such Information by Galapagos (and Galapagos shall be deemed to be the disclosing Party with respect to Product Information under Section 9.3 and Xxxxxx shall be deemed to be the receiving Party with respect thereto), but (ii) the disclosure by Galapagos to Xxxxxx of Product Information shall not cause such information to cease to be subject to the provisions of this Section 9.1 with respect to the use and disclosure of such Confidential Information by Galapagos. If this Agreement is terminated in its entirety or with respect to the Terminated Territory, this Section 9.1 shall have no continuing force or effect with respect to the use or disclosure of such information solely in connection with the Exploitation of the Licensed Compound or Licensed Product for the benefit of the Terminated Territory, but the Product Information, to the extent disclosed by Xxxxxx to Galapagos hereunder, shall continue to be Confidential Information of Xxxxxx, subject to the terms of Sections 9.2, 9.3, and 9.7 for purposes of the surviving provisions of this Agreement.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!